Recombinant Human CFHR5 (C-6His)

Item number: EPT124
Availability: In Stock
$469.00
$469.00
Please hurry! Only 100 left in stock

Documents

Size: 50ug
Subtotal: $469.00
10 customers are viewing this product

Customized & fast shipping

Terms and Conditions

Recombinant Human CFHR5 (C-6His)

Recombinant Human CFHR5 (C-6His)

$469.00

Recombinant Human CFHR5 (C-6His)

$469.00
Size: 50ug
Description
Recombinant Human Complement Factor H-Related 5 is produced by our Mammalian expression system and the target gene encoding Glu19-Glu569 is expressed with a 6His tag at the C-terminus.
Accession
Q9BXR6
Molecular weight
63.5 KDa
Apparent molecular weight
61 KDa, reducing conditions
Other names
Complement factor H-related protein 5; CFHR5; CFHL5; FHR5
Purity
Greater than 95% as determined by reducing SDS-PAGE.
Endotoxin
Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Redissolve
Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage
Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Delivery condition
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Complement factor H-related protein 5(FHR-5 for short), is a secreted protein which contains 9 Sushi (CCP/SCR) domains. It is expressed by the liver and secreted in plasma. The pattern of the deposits is similar to other complement components, suggesting that FHR-5 may play a role in complement activation and regulation. Defects in CFHR5 have been found in patients with atypical hemolytic uremic syndrome and may contribute to the disease. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease.

Related Products

Recently Viewed Products